Medicus Pharma Ltd. Common Stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Raza Bokhari
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Conshohocken State Road West Conshohocken PA Canada 19428
- IPO Date
- Nov 15, 2024
- CIK
- 0001997296
- Website
- medicuspharma.com
- Similar Companies
- Business
- Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech and life sciences company that focuses on accelerating the clinical development and commercialization of novel and disruptive therapeutic assets through acquisitions, partnerships and targeted investments. The company develops SkinJect, a patented dissolvable doxorubicin-containing microneedle array (D-MNA) as a non-invasive treatment for basal cell carcinoma and other non-melanoma skin cancers via ongoing Phase 2 trials including SKNJCT-003 in the United States and Europe and SKNJCT-004 in the United Arab Emirates; through its August 2025 acquisition of Antev Limited, it now advances Teverelix trifluoroacetate, a next-generation long-acting GnRH antagonist formulated as a microcrystalline suspension for sustained release every six weeks to treat acute urinary retention relapse in enlarged prostate patients and advanced prostate cancer in high cardiovascular-risk individuals, with FDA-approved Phase 2b study designs for 390 and 40 patients respectively. Medicus Pharma operates across three continents with clinical activities in the United States, United Kingdom, United Arab Emirates and Europe; founded in 2008, it maintains headquarters in Conshohocken, Pennsylvania, with prior Canadian operations in Toronto. Recent developments include the September 2025 acquisition of 98.6% of Antev for $2.97 million in cash plus 1.6 million shares and up to $65 million in contingent milestone payments tied to FDA approvals, adding Teverelix and industry veteran Patrick J. Mahaffy to its board; a strategic October 2025 collaboration with the Gorlin Syndrome Alliance to pursue FDA Expanded Access for SkinJect in patients with multiple recurrent basal cell carcinomas; an August 2025 non-binding memorandum of understanding with Helix Nanotechnologies to explore co-development of thermostable mRNA infectious disease vaccines combining microneedle delivery; positive FDA Type C meeting feedback in September 2025 supporting the 505(b)(2) pathway for SkinJect; full UK regulatory approvals in November 2025 to expand SKNJCT-003; and first patient dosing in SKNJCT-004. Subsidiaries include SkinJect Inc. and Antev Limited, with operations targeting unmet needs in oncology and urology for improved patient safety, efficacy and compliance.
Company News
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Wall Street sets positive tone as investors digest hotter inflation data
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
Dow falls as Treasury yields jump to highest level since 2023
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma advances pipeline during Q2 with key milestones
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SK Hynix backed by Wedbush as memory undersupply persists
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI